支气管哮喘,简称哮喘,是儿童时期最常见的慢性呼吸道疾病,临床以气流受限为主,并表现出长期慢性咳嗽(晨起和夜间发作或加剧),反复发作的喘息、胸闷等症状。在我国随着城市化和工业化水平的提高,哮喘发病水平在10年间平均上升64.84%[1]。资料显示,我国0~12岁儿童发病率约为3.12%[2-3]。哮喘治疗是一个长期、持续、规范、个体化的过程,吸入糖皮质激素(ICS)是目前治疗慢性气道炎症、改善哮喘症状 Bronchial asthma, or asthma for short, is the most common chronic respiratory disease in childhood. It is clinically limited by airflow limitation and shows long-term chronic cough (episodes or intensions of morning and night), recurrent wheezing and chest tightness. In China, with the improvement of urbanization and industrialization, the incidence of asthma increased by 64.84% on average in 10 years [1]. Data show that the incidence of children aged 0-12 years in China is about 3.12% [2-3]. Asthma treatment is a long-term, continuous, normative, individualized process in which inhaled corticosteroids (ICS) are currently used to treat chronic airway inflammation and improve asthma symptoms